Clinical efficacy of metformin in familial adenomatous polyposis and the effect of intestinal flora.
Orphanet J Rare Dis
; 19(1): 88, 2024 Feb 25.
Article
in En
| MEDLINE
| ID: mdl-38403687
ABSTRACT
BACKGROUND AND AIMS:
Metformin has been reported to inhibit the occurrence and development of colorectal cancer (CRC) by mediating changes in intestinal flora. Studies have also indicated that the occurence of familial adenomatous polyposis (FAP) may also be associated with changes in the intestinal flora. Therefore, we investigated the efficacy and safety of metformin in treating FAP and the association with intestinal flora.RESULTS:
Compared with the baseline, the mean number and load of polyps in the areas of nanocarbon labeling and postoperative residuals in the test group were lower than those in the placebo group, while the diversity of intestinal flora species was increased. At the genus level, the relative abundance of g_Ruminococcus in the test group was lower than that at baseline, whereas the relative abundance of g_Lactobacillus was higher. These changes were statistically significant (P < 0.05).CONCLUSION:
One-year metformin therapy for FAP is safe and effective, potentially mediated by modulating the intestinal flora. This study provides new insights and strategies for preventing adenomatous polyp carcinogenesis in FAP and explores possible preventive action.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Adenomatous Polyposis Coli
/
Gastrointestinal Microbiome
Limits:
Humans
Language:
En
Journal:
Orphanet J Rare Dis
Journal subject:
MEDICINA
Year:
2024
Document type:
Article
Affiliation country:
China